Biomedicina predictiva e investigación traslacional de las enfermedades respiratorias, cardiovasculares y metabólicas
BIOPRE
Hospital Universitari de Girona Dr. Josep Trueta
Girona, EspañaPublicacións en colaboración con investigadores/as de Hospital Universitari de Girona Dr. Josep Trueta (24)
2024
-
Combining loop with thiazide diuretics in patients discharged home after a heart failure decompensation: Association with 30-day outcomes
European Journal of Internal Medicine, Vol. 127, pp. 126-133
-
Effect of early initiation of noninvasive ventilation in patients transported by emergency medical service for acute heart failure
European Journal of Emergency Medicine, Vol. 31, Núm. 5, pp. 339-346
-
Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis
Leukemia
-
Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib
Annals of Hematology
-
The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis
American Journal of Hematology
2023
-
Impact of congestion and perfusion status in the emergency department on severity of decompensation and short-term prognosis in patients with acute heart failure
European Heart Journal: Acute Cardiovascular Care, Vol. 12, Núm. 3, pp. 165-174
-
Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors
Cancers, Vol. 15, Núm. 4
2022
-
Short-term outcomes by chronic betablocker treatment in patients presenting to emergency departments with acute heart failure: BB-EAHFE
European Heart Journal: Acute Cardiovascular Care, Vol. 11, Núm. 10, pp. 761-771
2021
-
Bronchial Thermoplasty Global Registry (BTGR): 2-year results
BMJ Open, Vol. 11, Núm. 12
-
Frequency of five cardiovascular/hemostatic entities as primary manifestations of SARS-CoV-2 infection: Results of the UMC-19-S2
International Journal of Cardiology, Vol. 330, pp. 268-272
-
Incidence, risk factors, clinical characteristics and outcomes of deep venous thrombosis in patients with COVID-19 attending the Emergency Department: results of the UMC-19-S8
European Journal of Emergency Medicine, Vol. 28, Núm. 3, pp. 218-226
-
Pulmonary embolism in patients with COVID-19: incidence, risk factors, clinical characteristics, and outcome
European heart journal, Vol. 42, Núm. 33, pp. 3127-3142
2020
-
Evaluación de las características clínicas y evolución de pacientes con COVID-19 a partir de una serie de 1000 pacientes atendidos en servicios de urgencias españoles
Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias, Vol. 32, Núm. 4, pp. 233-241
-
Identification of Senior At Risk scale predicts 30-day mortality among older patients with acute heart failure
Medicina Intensiva, Vol. 44, Núm. 1, pp. 9-17
2019
-
Acute heart failure and adverse events associated with the presence of renal dysfunction and hyperkalaemia. EAHFE- renal dysfunction and hyperkalaemia
European Journal of Internal Medicine, Vol. 67, pp. 89-96
-
Influence of the length of hospitalisation in post-discharge outcomes in patients with acute heart failure: Results of the LOHRCA study
European Journal of Internal Medicine, Vol. 70, pp. 24-32
-
Patients with acute heart failure discharged from the emergency department and classified as low risk by the MEESSI score (Multiple risk estimate based on the Spanish emergency department scale): Prevalence of adverse events and predictability
Emergencias, Vol. 31, Núm. 1, pp. 5-14
2018
-
Effects on short term outcome of non-invasive ventilation use in the emergency department to treat patients with acute heart failure: A propensity score-based analysis of the EAHFE Registry
European Journal of Internal Medicine, Vol. 53, pp. 45-51
2017
-
Cost-effectiveness and cost-utility analysis of apixaban versus dabigatran and rivaroxaban in the treatment and secondary prevention of venous thromboembolism
Pharmacoeconomics - Spanish Research Articles, Vol. 14, Núm. 1, pp. 7-18
2016
-
Cost-effectiveness analysis of apixaban compared to low-molecular-weight heparins and Vitamin K antagonists for treatment and secondary prevention of venous thromboembolism
Farmacia Hospitalaria, Vol. 40, Núm. 3, pp. 187-208